List of Incivek drug patents
Incivek is owned by Vertex Pharms.
Incivek contains Telaprevir.
Incivek has a total of 2 drug patents out of which 0 drug patents have expired.
Incivek was authorised for market use on 23 May, 2011.
Incivek is available in tablet;oral dosage forms.
Incivek can be used as method of treating chronic hepatitis c.
The generics of Incivek are possible to be released after 30 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(1 year, 8 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(4 years from now) | |
Drugs and Companies using TELAPREVIR ingredient
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
INCIVEK family patents
15
United States
12
Korea, Republic of
11
European Union
9
China
8
Taiwan
6
Japan
5
Norway
4
Germany
4
Spain
3
Canada
3
Hong Kong
3
Australia
3
Israel
2
Ukraine
2
Denmark
2
Mexico
2
New Zealand
2
EA
2
Ecuador
2
Austria
1
Chile
1
Slovakia
1
Peru
1
Poland
1
Slovenia
1
Luxembourg
1
El Salvador
1
Brazil
1
Algeria
1
Cyprus
1
Czech Republic
1
Croatia
1
Argentina
1
Hungary
1
South Africa
1
Portugal
1
Russia
1
Malaysia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic